Pellicori Pierpaolo, Salekin Damien, Pan Daniel, Clark Andrew L
a Department of Cardiology , Hull York Medical School (University of Hull), Castle Hill Hospital , Kingston upon Hull , UK.
Expert Rev Cardiovasc Ther. 2017 May;15(5):389-396. doi: 10.1080/14779072.2017.1317592. Epub 2017 Apr 17.
Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are two common, heterogeneous, long-term illnesses which cause significant morbidity and mortality. Although they both present with breathlessness, they are treated differently. Treatment of COPD focuses mainly on relieving short-term breathlessness, whilst treatment of HF has focused on long term morbidity and mortality. Areas covered: In this review, we aim to highlight the diagnostic challenges in distinguishing COPD from HF. We also explore the implications of their overlap, and the use of biomarkers and treatments for HF in patients with COPD to improve long-term outcomes. Expert commentary: Cardiovascular morbidity and mortality amongst patients with COPD is substantial. Approaches which identify patients with COPD at highest cardiovascular risk may therefore be helpful. A trial targeting those patients with COPD and raised natriuretic peptide levels might be the way to test whether cardiovascular medication has anything to offer the respiratory patient.
心力衰竭(HF)和慢性阻塞性肺疾病(COPD)是两种常见的、异质性的长期疾病,会导致显著的发病率和死亡率。尽管它们都表现为呼吸急促,但治疗方法不同。COPD的治疗主要侧重于缓解短期呼吸急促,而HF的治疗则侧重于长期发病率和死亡率。涵盖领域:在本综述中,我们旨在强调区分COPD和HF时的诊断挑战。我们还探讨了它们重叠的影响,以及在COPD患者中使用生物标志物和HF治疗方法以改善长期预后。专家评论:COPD患者的心血管发病率和死亡率很高。因此,识别心血管风险最高的COPD患者的方法可能会有所帮助。针对那些COPD且利钠肽水平升高的患者进行试验,可能是检验心血管药物是否能为呼吸疾病患者带来益处的途径。